Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
GHK-Cus gene modulation capacity was documented in a landmark microarray analysis by Pickart et al., identifying 4,000+ gene targets including VEGF upregulation (angiogenesis), SOD2 upregulation (oxidative defense), and downregulation of pro-inflammatory cytokine genes including TNF- and IL-6
World J Microbiol Biotechnol 33 , 106 (2017)
For example, in December 2024, Novo Nordisk bought three Catalent sites for US$11bn in order to boost its injectable drug capacity, and in December 2025, Eli Lilly announced new plans to build a US$6bn manufacturing facility in the US
GHK-Cu has extensive preclinical research (cell studies and animal models) with strong, consistent results
US$ 23.71
US$ 25.89
US$ 29.80
